首页> 美国卫生研究院文献>Neuro-Oncology >EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE

【2h】

EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE

机译：EPID-07。用替替莫唑胺治疗的胶质母细胞瘤患者的血液学不良事件

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Temozolomide (TMZ) is the cornerstone for glioblastoma (GBM) treatment. A significant proportion of patients develops hematologic toxicities with limited investigations on outcomes and risk factors for their development.

机译：Temozolomide（TMZ）是胶质母细胞瘤（GBM）处理的基石。大部分患者发育血液学毒性，对其发展的结果和风险因素有限调查。

著录项

期刊名称 Neuro-Oncology
作者
Catherine Garcia; Zin Myint; Rani Jayswal; Allison Butts; Heidi Weiss; John Villano;
展开▼
作者单位

展开▼
年(卷),期 2019(21),Suppl 6
年度 2019
页码 vi75–vi76
总页数 2
原文格式 PDF
正文语种
中图分类神经病学;肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone [J] . Guzauskas G. F., Pollom E., Wang B. C. M. International Journal of Radiation Oncology, Biology, Physics . 2018,第3Suppla期

机译：植物血管瘤患者的平均寿命生存估计增加65岁及以上的肿瘤治疗田间和替代毒物治疗的患者单独治疗
2. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system [J] . Giselle Sarganas, Hans D. Orzechowski, Andreas Klimpel, Neuro-Oncology . 2012,第5期

机译：替莫唑胺治疗多形性胶质母细胞瘤患者的严重持续性胆汁淤积性肝炎：案例研究和FDA不良事件报告系统的数据审查
3. Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases [J] . Lombardi Giuseppe, Caccese Mario, Bellu Luisa, Anti-cancer drugs . 2018,第9期

机译：伴随放疗和替替莫唑族治疗期间严重血液毒性患者维持造粒虫治疗巨粒瘤患者的良好耐受性：两种情况报告
4. Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: a 4D simulation model of the tumor response [C] . V.P. Antipas, G.S. Stamatakos, N.K. Uzunoglu . 2005

机译：替莫唑胺在体内治疗多形性胶质母细胞瘤：肿瘤反应的4D模拟模型
5. Immune-Related Adverse Events in Cancer Patients Being Treated with Immune Checkpoint Inhibitors [D] . Byrne, Margaret M. 2021

机译：用免疫检查点抑制剂治疗癌症患者免疫相关不良事件
6. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system [O] . Giselle Sarganas, Hans D. Orzechowski, Andreas Klimpel, 2012

机译：替莫唑胺治疗多形性胶质母细胞瘤患者的严重持续性胆汁淤积性肝炎：案例研究和FDA不良事件报告系统的数据审查
7. Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone [O] . G.F. Guzauskas, E. Pollom, B.C.M. Wang 2018

机译：植物血管瘤患者的平均寿命生存估计增加65岁及以上的肿瘤治疗田间和替代毒物治疗的患者单独治疗

EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅